Innate Pharma FY2025 EPS Forecast Increased by HC Wainwright

Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) – Analysts at HC Wainwright raised their FY2025 EPS estimates for shares of Innate Pharma in a research note issued to investors on Thursday, September 18th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn ($0.66) per share for the year, up from their prior forecast of ($0.82). HC Wainwright has a “Neutral” rating on the stock. HC Wainwright also issued estimates for Innate Pharma’s FY2026 earnings at ($0.68) EPS.

A number of other brokerages have also recently weighed in on IPHA. Leerink Partners restated a “market perform” rating and set a $2.00 price objective (down from $10.00) on shares of Innate Pharma in a research note on Thursday. BTIG Research initiated coverage on shares of Innate Pharma in a report on Monday, July 28th. They issued a “buy” rating for the company. Finally, Leerink Partnrs cut Innate Pharma from a “strong-buy” rating to a “hold” rating in a report on Thursday. One analyst has rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, Innate Pharma currently has an average rating of “Hold” and an average price target of $6.50.

Innate Pharma Stock Down 3.6%

Innate Pharma stock opened at $1.87 on Monday. Innate Pharma has a 52-week low of $1.29 and a 52-week high of $3.51. The company has a debt-to-equity ratio of 3.52, a current ratio of 2.21 and a quick ratio of 2.60. The firm has a 50-day moving average price of $2.06 and a two-hundred day moving average price of $2.02.

About Innate Pharma

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.